Twitter Facebook
Contact the Author | sample_mail@mail.com

13 Jul

The Lancet Oncolgy. Vol.16, No.4, e190-e194. April 2015 Personel View Authors: Prof. David Ashley PhD, Prof. David Thomas Ph.D, Prof. Lisa Gore MD, Prof. Rob Carter Ph.D, Prof. John R Zalcberg Ph.D, Prof.Renee Otmar Ph.D, Prof Julian Savulescu Ph.D Summary Rare cancers collectively contribute a disproportionate fraction of the total burden of cancer. The oncology community is increasingly facing small numbers of patients with each cancer subtype, requiring cooperation and collaboration to complete multicentre trials that advance knowledge and patient care……

Read more

13 Jun

The Lancet. Vol.385 April 4th 2015. Pgs 1279-1280 Medicines in Europe could spin out of control unless authorities act urgently to create a central base of supply disruptions, adopt preventive measures, and draw up contingency plans to ensure patients’ lives are not endangered, says health professionals. A report published by the European Association of Hospital Pharmacists (EAHP)  last November showed 86% of 607 practitioners in 36 Europeans countries had sourcing problems, and 66% said this problem arose on a daily…..

Read more

13 Jun

Osteosarcoma: mixed efficacy of sorafenib and everolimus treatment Consult the Pubmed abstract. Lancet Oncol.;S1470-2045(14)71136-2; December 2014 To read more on Osteosarcoma

Read more

12 May

This is very encouraging news! Author Chris Lancashire in her autobiography called ‘Beyond Courage” is highlighting this ‘Forgotten Cancers Project” launched on the 26th August 2011. In this project 15 ‘Target Cancers ‘ had been selected for specific reasons such as poor survival rate and or limited understanding of their causes. One of these Target Cancers is bone cancer. In her book, the author is raising community and global awareness of this rarest bone cancer, Chondroblastic Osteosarcoma. Read below :…..

Read more

11 Feb

Sharing this very interesting, latest development by University of East Anglia. Researchers at University Of East Anglia, Norwich, UK, hope a simple blood test could allow them to catch the disease quicker. Bone cancer is typically more aggressive than others, with some forms resistant to chemotherapy and radiotherapy, leaving limb amputation as the only option. Even with this drastic surgery, recurrence of the tumour is extremely common and overall survival rates are low- with only 10 percent of patients living…..

Read more

11 Feb

Sharing this report by the McKell Institute Australia, published in OrphaNews, the newsletter of The Rare Disease Community, on the 17th January 2015. This report is also supported by Rare Voices Australia www.rarevoices.org.au http://mckellinstitute.org.au A report by the McKell Institute Australia has concluded that Australia’s system of funding rare diseases, conducted by the Life Saving Drug Program (LSDP) is in need of reform. This informative report highlights several challenges involved in bringing treatments for rare disease patients in Australia. The…..

Read more

30 Jan

A scientific discovery by Melbourne Researchers, Drs. Carl Walkley and his team at St.Vincent’s Institute of Medical Research(SVIMR) Australia, offering sufferers of the 5th most common cancer in children a glimmer of hope. The survival rate for Osteosarcoma, a tumour of the bone, has remained unchanged for 3 decades. The researchers at SVIMR has uncovered how a key hormone and receptor helps the tumour survive, paving the way to better treatments. Dr. Walkley said patients who have recurrent Osteosarcoma,or a…..

Read more

31 Dec

18th November 2013 Book Launch at Readings, Book Store, Hawthorn, Victoria, Australia. See YouTube for video link

Read more

30 Dec

It has been a while, but it is finally up and running. Thank you for your patience over the year. I will be updating you in the New Year 2015, and of the highlights and events of 2014. Hope you had a Good Christmas. Wishing you all a Very Happy New Year 2015!

Read more